Iovance Biotherapeutics grants inducement stock options to 27 new employees
Iovance Biotherapeutics, Inc. granted inducement stock options for 140,860 shares to 27 new non-executive employees on June 18, 2026. The options, priced at $3.91 per share, vest over three years with specific milestones. This move aligns with the company’s strategy to attract talent under its 2021 Inducement Plan.
*this image is generated using AI for illustrative purposes only.
Iovance Biotherapeutics, Inc. granted inducement stock options covering an aggregate of 140,860 shares of common stock to twenty-seven new, non-executive employees. The grants were approved on June 18, 2026, under the company’s Amended and Restated 2021 Inducement Plan. These awards were authorized by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price of $3.91, which was the closing price of Iovance’s common stock on the Date of Grant. The vesting schedule spans a three-year period, with one-third of the shares vesting on the first anniversary of the employee’s start date. The remaining shares vest in eight quarterly installments over the subsequent two years, starting from the first quarter after the First Vesting Date, contingent upon continued employment.
Grant Details
| Detail | Value |
|---|---|
| Total shares granted | 140,860 |
| Number of employees | 27 |
| Exercise price per share | $3.91 |
| Vesting period | 3 years |
Iovance Biotherapeutics, Inc. is a biotechnology company focused on developing novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients. The company’s TIL platform has shown clinical data across multiple solid tumors, and its product Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication.
How might the addition of 27 new employees impact Iovance's operational capacity and R&D timelines?
What strategic roles are these new hires expected to fill, and how do they align with the company's growth objectives?
Could this hiring spree signal upcoming clinical trials or expansion of Iovance's TIL therapy pipeline?
19
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
